Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer is a phase 1/2, interventional study registered as NCT06980532 by Liu Huang, with a registry enrolment figure of 42 participants, started 2025-04-25 and due to reach its primary completion in 2028-12-30. Interventions recorded: Glumetinib Combined with Fruquintinib. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Recommended dose for Phase II; Objective response rate(ORR). Colorectal eligibility wording from the registry: "Patients with unresectable metastatic colorectal cancer with microsatellite stable (MSS) confirmed by pathology or histology;". Sites: China. No results are recorded here; the registry entry is the source.